Analysts expect Corium International Inc (NASDAQ:CORI) to announce earnings per share of ($0.41) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Corium International’s earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.42). Corium International posted earnings per share of ($0.42) in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.4%. The business is expected to issue its next quarterly earnings report on Thursday, May 10th.
On average, analysts expect that Corium International will report full-year earnings of ($1.43) per share for the current year, with EPS estimates ranging from ($1.58) to ($1.19). For the next year, analysts forecast that the business will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.69) to ($0.84). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Corium International.
Corium International (NASDAQ:CORI) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. The company had revenue of $9.32 million during the quarter, compared to the consensus estimate of $7.48 million. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%.
A number of equities research analysts have commented on CORI shares. BidaskClub raised shares of Corium International from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. HC Wainwright set a $14.00 target price on shares of Corium International and gave the stock a “buy” rating in a research report on Wednesday, December 27th. Needham & Company LLC cut their target price on shares of Corium International from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, December 26th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $14.00 target price on shares of Corium International in a research report on Friday, December 22nd. Finally, ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $12.86.
Shares of Corium International (NASDAQ CORI) traded up $0.03 on Friday, hitting $13.27. 311,200 shares of the company traded hands, compared to its average volume of 192,990. The company has a market capitalization of $479.36, a P/E ratio of -8.45 and a beta of 1.59. The company has a quick ratio of 1.34, a current ratio of 1.40 and a debt-to-equity ratio of 5.91. Corium International has a 12 month low of $3.44 and a 12 month high of $13.93.
In other Corium International news, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were acquired at an average price of $11.83 per share, for a total transaction of $595,640.50. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The shares were acquired at an average price of $12.54 per share, for a total transaction of $6,395,400.00. The disclosure for this purchase can be found here. Insiders own 30.80% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. RTW Investments LP boosted its stake in shares of Corium International by 1.4% during the 4th quarter. RTW Investments LP now owns 1,699,653 shares of the biopharmaceutical company’s stock worth $16,334,000 after acquiring an additional 24,174 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Corium International by 42.1% during the 4th quarter. BlackRock Inc. now owns 1,679,815 shares of the biopharmaceutical company’s stock worth $16,143,000 after acquiring an additional 497,615 shares during the last quarter. Opaleye Management Inc. boosted its stake in shares of Corium International by 15.2% during the 4th quarter. Opaleye Management Inc. now owns 1,060,000 shares of the biopharmaceutical company’s stock worth $10,186,000 after acquiring an additional 140,000 shares during the last quarter. Tamarack Advisers LP boosted its stake in shares of Corium International by 6.3% during the 4th quarter. Tamarack Advisers LP now owns 1,010,000 shares of the biopharmaceutical company’s stock worth $9,706,000 after acquiring an additional 60,000 shares during the last quarter. Finally, State Street Corp purchased a new position in shares of Corium International during the 2nd quarter worth $1,840,000. Institutional investors and hedge funds own 87.29% of the company’s stock.
WARNING: This story was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/14/brokerages-expect-corium-international-inc-cori-to-post-0-41-eps.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.